{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:56:46Z","timestamp":1792205806918,"version":"4.4.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274386"],"award-info":[{"award-number":["82274386"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374417"],"award-info":[{"award-number":["82374417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174287"],"award-info":[{"award-number":["82174287"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejphar.2025.177874","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T10:48:35Z","timestamp":1750762115000},"page":"177874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["B1344 ameliorates non-alcoholic steatohepatitis in HFCD-HF\/G-induced mice: exploring the therapeutic efficacy and mechanism of a novel FGF21 analogue"],"prefix":"10.1016","volume":"1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4664-5977","authenticated-orcid":false,"given":"Zhiwei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9337-8912","authenticated-orcid":false,"given":"Siyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2155-8110","authenticated-orcid":false,"given":"Haiyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177874_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1150222","article-title":"Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho","volume":"14","author":"Aaldijk","year":"2023","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177874_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177874_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47719-y","article-title":"Characterization of subcutaneous and omental adipose tissue in patients with obesity and with different degrees of glucose impairment","volume":"9","author":"Belligoli","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177874_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155873","article-title":"Pegozafermin, a FGF21 analog, for the treatment of non-alcoholic steatohepatitis (NASH) patients with F2\/F3 fibrosis","volume":"153","author":"Bhatt","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2025.177874_bib5","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -Independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2025.177874_bib6","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","volume":"65","author":"Bril","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.177874_bib7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41467-020-14384-z","article-title":"Fasting-induced FGF21 signaling activates hepatic autophagy and lipid degradation via JMJD3 histone demethylase","volume":"11","author":"Byun","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2025.177874_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1089214","article-title":"The potential function and clinical application of FGF21 in metabolic diseases","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177874_bib9","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2023.01.039","article-title":"Albumin-fused long-acting FGF21 analogue for the treatment of non-alcoholic fatty liver disease","volume":"355","author":"Chikamatsu","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejphar.2025.177874_bib10","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1172\/JCI141828","article-title":"Decreased adipose tissue oxygenation associates with insulin resistance in individuals with obesity","volume":"130","author":"Cifarelli","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177874_bib11","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2337\/db20-0209","article-title":"The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman Primates","volume":"69","author":"Cui","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177874_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","article-title":"Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications","volume":"142","author":"Cusi","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2025.177874_bib13","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/en.2012-1193","article-title":"TNF-alpha represses beta-klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway","volume":"153","author":"Diaz-Delfin","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.177874_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109222","article-title":"Immune regulation of poly unsaturated fatty acids and free fatty acid receptor 4","volume":"112","author":"Duah","year":"2023","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.ejphar.2025.177874_bib15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41574-023-00939-9","article-title":"A pivotal year for NAFLD and NASH therapeutics","volume":"20","author":"Dufour","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177874_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.177874_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jacc.2011.01.051","article-title":"Reduced adipose tissue inflammation represents an intermediate cardiometabolic phenotype in obesity","volume":"58","author":"Farb","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejphar.2025.177874_bib18","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/sj.ijo.0802399","article-title":"Adipocyte functions are modulated by cell size change: potential involvement of an integrin\/ERK signalling pathway","volume":"27","author":"Farnier","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.ejphar.2025.177874_bib19","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2025.177874_bib20","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2025.177874_bib21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s42255-021-00354-2","article-title":"Metabolic messengers: FGF21","volume":"3","author":"Flippo","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejphar.2025.177874_bib22","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon Tacer","year":"2010","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177874_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abe2480","article-title":"3D microscopy and deep learning reveal the heterogeneity of crown-like structure microenvironments in intact adipose tissue","volume":"7","author":"Geng","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejphar.2025.177874_bib24","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1016\/j.celrep.2019.02.014","article-title":"Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues","volume":"26","author":"Geng","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejphar.2025.177874_bib25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41580-023-00680-1","article-title":"White adipocyte dysfunction and obesity-associated pathologies in humans","volume":"25","author":"Hagberg","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejphar.2025.177874_bib26","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.drudis.2017.06.007","article-title":"Mouse models of nonalcoholic steatohepatitis in preclinical drug development","volume":"22","author":"Hansen","year":"2017","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2025.177874_bib27","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2025.177874_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177874_bib29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ebiom.2019.08.069","article-title":"Senolytics decrease senescent cells in humans: preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease","volume":"47","author":"Hickson","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2025.177874_bib30","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177874_bib31","doi-asserted-by":"crossref","first-page":"10867","DOI":"10.1074\/jbc.M116.719120","article-title":"The nuclear receptor rev-erbalpha regulates adipose tissue-specific FGF21 signaling","volume":"291","author":"Jager","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2025.177874_bib32","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1016\/j.ymthe.2024.10.023","article-title":"Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy","volume":"32","author":"Jimenez","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2025.177874_bib33","doi-asserted-by":"crossref","first-page":"C375","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2025.177874_bib34","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.177874_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.molmet.2013.12.003","article-title":"Inventing new medicines: the FGF21 story","volume":"3","author":"Kharitonenkov","year":"2014","journal-title":"Mol. Metabol."},{"key":"10.1016\/j.ejphar.2025.177874_bib36","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.177874_bib37","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2025.177874_bib38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.177874_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155329","article-title":"Genome-wide association and Mendelian randomization study of fibroblast growth factor 21 reveals causal associations with hyperlipidemia and possibly NASH","volume":"137","author":"Larsson","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2025.177874_bib40","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.cgh.2018.11.023","article-title":"Population-Based trends in prevalence of nonalcoholic fatty liver disease in US adults with type 2 diabetes","volume":"17","author":"Le","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2025.177874_bib41","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","article-title":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism","volume":"1","author":"Lefere","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.ejphar.2025.177874_bib42","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1007\/s00018-016-2161-x","article-title":"Pathogenesis of nonalcoholic steatohepatitis","volume":"73","author":"Liu","year":"2016","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejphar.2025.177874_bib43","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2174\/1389450116666150427155342","article-title":"Antioxidant mechanisms in nonalcoholic fatty liver disease","volume":"16","author":"Liu","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2025.177874_bib44","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2468-1253(22)00347-8","article-title":"Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b\/2a multiple-ascending-dose study","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2025.177874_bib45","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/MEG.0b013e32835609b0","article-title":"How adiponectin, leptin, and ghrelin orchestrate together and correlate with the severity of nonalcoholic fatty liver disease","volume":"24","author":"Machado","year":"2012","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2025.177874_bib46","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2265.2008.03502.x","article-title":"Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity","volume":"71","author":"Mraz","year":"2009","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177874_bib47","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in compensated liver cirrhosis caused by MASH","author":"Noureddin","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2025.177874_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009997","article-title":"The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity","volume":"5","author":"O'Connell","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2025.177874_bib49","doi-asserted-by":"crossref","first-page":"7432","DOI":"10.1073\/pnas.0701600104","article-title":"BetaKlotho is required for metabolic activity of fibroblast growth factor 21","volume":"104","author":"Ogawa","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2025.177874_bib50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/01.mcg.0000212651.05656.5b","article-title":"Abnormal glucose tolerance and non-esterified fatty acids (NEFAs) as predictors of non-alcoholic steatohepatitis (NASH): which Ash that ignites the NASH","volume":"41","author":"Osman","year":"2007","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2025.177874_bib51","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1126\/science.1103160","article-title":"Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes","volume":"306","author":"Ozcan","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2025.177874_bib52","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.3390\/cells9122683","article-title":"Capillary rarefaction in obesity and metabolic diseases-organ-specificity and possible mechanisms","volume":"9","author":"Paavonsalo","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.177874_bib53","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2025.177874_bib54","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.177874_bib55","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2025.177874_bib56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2025.177874_bib57","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1100\/2011\/397971","article-title":"Macrophages, meta-inflammation, and immuno-metabolism","volume":"11","author":"Shapiro","year":"2011","journal-title":"Sci. World J."},{"key":"10.1016\/j.ejphar.2025.177874_bib58","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1210\/jc.2006-1055","article-title":"Relationship between adipocyte size and adipokine expression and secretion","volume":"92","author":"Skurk","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.177874_bib59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41366-021-00757-x","article-title":"Cellular senescence and its role in white adipose tissue","volume":"45","author":"Smith","year":"2021","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.ejphar.2025.177874_bib60","article-title":"The nuanced metabolic functions of endogenous FGF21 depend on the nature of the stimulus, tissue source, and experimental model","volume":"12","author":"Spann","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177874_bib61","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cmet.2016.04.011","article-title":"Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk","volume":"23","author":"Stern","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2025.177874_bib62","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1016\/j.bbadis.2015.02.012","article-title":"Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet","volume":"1852","author":"Tanaka","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2025.177874_bib63","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.177874_bib64","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/hep.22350","article-title":"Visceral fat: a key mediator of steatohepatitis in metabolic liver disease","volume":"48","author":"van der Poorten","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2025.177874_bib65","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/s41598-018-22962-x","article-title":"Abdominal subcutaneous and visceral adipocyte size, lipolysis and inflammation relate to insulin resistance in male obese humans","volume":"8","author":"Verboven","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2025.177874_bib66","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.3390\/cells10123300","article-title":"Recent advances in adipose tissue dysfunction and its role in the pathogenesis of non-alcoholic fatty liver disease","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejphar.2025.177874_bib67","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13098-025-01680-1","article-title":"Plin5: a potential therapeutic target for type 2 diabetes mellitus","volume":"17","author":"Wei","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.ejphar.2025.177874_bib68","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s42255-021-00483-8","article-title":"The metabolic roots of senescence: mechanisms and opportunities for intervention","volume":"3","author":"Wiley","year":"2021","journal-title":"Nat. Metab."},{"key":"10.1016\/j.ejphar.2025.177874_bib69","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1210\/endo.141.6.7584","article-title":"Perspective: the insulin signaling system--a common link in the pathogenesis of type 2 diabetes","volume":"141","author":"Withers","year":"2000","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2025.177874_bib70","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1172\/JCI200319451","article-title":"Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance","volume":"112","author":"Xu","year":"2003","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2025.177874_bib71","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2174\/1389201015666140515124838","article-title":"Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation","volume":"14","author":"Ye","year":"2013","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.ejphar.2025.177874_bib72","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/j.1365-2362.2010.02338.x","article-title":"Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease","volume":"40","author":"Yilmaz","year":"2010","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2025.177874_bib73","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2025.177874_bib74","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925006284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T20:18:08Z","timestamp":1778876288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925006284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":74,"alternative-id":["S0014299925006284"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177874","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"B1344 ameliorates non-alcoholic steatohepatitis in HFCD-HF\/G-induced mice: exploring the therapeutic efficacy and mechanism of a novel FGF21 analogue","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177874","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177874"}}